- Zacks•3 days ago
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
- Benzinga•5 days ago
Following AstraZeneca plc (ADR) (NYSE: AZN )’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings ...
- American City Business Journals•6 days ago
AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,627.00 x 6100|
|Ask||4,627.50 x 13000|
|Day's Range||4,611.00 - 4,685.46|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||16.76|
|Dividend & Yield||2.80 (4.82%)|
|1y Target Est||N/A|